Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948758 | 0.85 | L3MBTL1 (0.47) | L3MBTL1KMT2APOLBFAAH | |
| SCHEMBL17232238 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2 | |
| SCHEMBL30948663 | 0.84 | ALDH1A1 (0.32) | L3MBTL1FAAH | |
| SCHEMBL14930732 | 0.80 | L3MBTL1 (0.46) | SMN1; SMN2L3MBTL1TDP1KMT2APOLB | |
| SCHEMBL30948678 | 0.80 | CTSK (0.31) | L3MBTL1TDP1FAAH | |
| SCHEMBL20465438 | 0.79 | CASP1 (0.39) | — | |
| Duazomycin SCHEMBL27800395 | 0.79 | MAPT (0.44) | SMN1; SMN2 | |
| SCHEMBL30948750 | 0.79 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL30919286 | 0.77 | KMT2A (0.40) | SMN1; SMN2L3MBTL1KMT2APOLB | |
| SCHEMBL29530690 | 0.77 | TLR2 (0.32) | L3MBTL1KMT2AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | SMN1; SMN2 688/4885L3MBTL1 320/4885TDP1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.